Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Mol Immunol. 2009 Mar 14;46(8-9):1647–1653. doi: 10.1016/j.molimm.2009.02.021

Figure 5.

Figure 5

Anti-fHbp mAb binding to mutants of a fHbp in the variant 3 group as measured by ELISA. Open squares, control WT fHbp in the variant 1 group (positive for JAR 4; negative for JAR 31); filled circles, control WT fHbp in the variant 3 group (negative for JAR 4; positive for JAR 31); shaded triangles, ΔKDN mutant of fHbp in the variant 3 group, which did not result in JAR 4 binding; asterisks, a double mutant of fHbp in the variant 3 group with ΔKDN and FKA->YGN, which resulted in partial expression of the JAR 4 epitope. A, Binding of JAR 4. B, Binding of a control anti-fHbp mAb, JAR 31, which recognizes an epitope in the C-domain (Beernink and Granoff, 2008). JAR 31 bound to WT fHbp in the variant 3 group and with the two mutants, but not with the WT fHbp in the variant 1 group.